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ABSTRACT 
Data from randomised controlled trials to guide antihypertensive agent choice for chronic 
hypertension in pregnancy are limited; this study aimed to compare labetalol and 
nifedipine, additionally assessing the impact of ethnicity on treatment efficacy. Pregnant 
women with chronic hypertension (12+0-27+6 weeks’ gestation) were enrolled at four UK 
centres (August 2014 to October 2015). Open-label first-line antihypertensive treatment 
was randomly assigned: labetalol (200-1800 mg/day) or nifedipine modified release (20-80 
mg/day). Analysis included 112 women (98%) who completed the study (labetalol n=55, 
nifedipine n=57). Maximum blood pressure (BP) post-randomisation was 161/101 mm Hg 
with labetalol versus 163/105 mm Hg with nifedipine (mean difference systolic: 1.2 mm Hg 
(-4.9 to 7.2 mm Hg), diastolic: 3.3 mm Hg (-0.6 to 7.3 mm Hg)). Mean BP was 134/84 mm Hg 
with labetalol and 134/85 mm Hg with nifedipine (mean difference systolic: 0.3 mm Hg (-2.8 
to 3.4 mm Hg), and diastolic: -1.9 mm Hg (-4.1 to 0.3 mm Hg)). Nifedipine use was 
associated with a 7.4 mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, 
measured by pulse wave analysis. No difference in treatment effect was observed in Black 
women (n=63), but a mean 4 mm Hg reduction (-6.6 to -0.8 mm Hg; P=0.015) in brachial 
diastolic BP was observed with labetalol compared to nifedipine in non-Black women 
(n=49). Labetalol and nifedipine control mean BP to target in pregnant women with chronic 
hypertension. This study provides support for a larger definitive trial scrutinising the 
benefits and side effects of first-line antihypertensive treatment. 
Key words: pregnancy complications, hypertension, antihypertensive agents, labetalol, 
nifedipine 
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INTRODUCTION 
Data to inform prescribing of antihypertensive treatments for chronic hypertension in 
pregnancy are sparse and subsequently no consensus on the optimal agent(s) exists.1, 2 The 
prevalence of chronic hypertension in pregnancy is estimated at 3%,3 but this figure is set to 
increase with rising maternal age and the global obesity epidemic.4, 5 Given that chronic 
hypertension is associated with significantly increased adverse maternal and perinatal 
outcomes compared to the general pregnant population,6 defining optimal antihypertensive 
treatment(s) is warranted.  
 
A Cochrane review examining trials (including over 4000 women) in mild to moderate 
hypertension in pregnancy (combining chronic and gestational hypertension) concluded that 
though the incidence of severe hypertension is reduced with antihypertensive treatment, no 
reduction in the incidence of adverse maternal and perinatal outcomes has been 
demonstrated.7 There have been additional concerns that antihypertensive treatment might 
increase the risk of fetal growth restriction.8 However, more recent evidence from the 
Control of Hypertension In Pregnancy Study  concluded that ‘tight control’ to a diastolic 
target of 85 mm Hg (compared to ‘less-tight control’ to a diastolic target of 105 mm Hg) did 
not increase the risk of pregnancy loss or high-level neonatal care in women with non-
severe chronic and gestational hypertension, no proteinuria and a singleton pregnancy.9 
This study also demonstrated that the incidence of severe maternal hypertension was 
significantly increased with ‘less-tight’ control, which was associated with an increased risk 
of serious maternal morbidity in these women (post-hoc analysis).10 The study highlights the 
need to determine which antihypertensive agent(s) provides optimal control of chronic 
hypertension in pregnancy to ameliorate these risks.  
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Choice of antihypertensive outside pregnancy depends on ethnicity with those of 
African/Caribbean family origin receiving calcium-channel blockers as first-line agent11 and is 
thought to relate to differences in the pathophysiology causing hypertension in those of 
differing ethnic backgrounds.12 Ethnic disparity in maternal and perinatal outcome in the 
general pregnant population is well described and likely to be multifactorial.13 To our 
knowledge, no randomised controlled trials have investigated the impact of ethnicity on 
efficacy of antihypertensive treatment in pregnancy. The aims of the ‘Pregnancy And 
chronic hypertension: NifeDipine versus lAbetalol as antihypertensive treatment’  study 
were three-fold: to assess feasibility of such a randomised controlled trial, to evaluate 
mechanistic treatment effects, and to examine the impact of ethnicity on efficacy of 
nifedipine (a calcium-channel blocker with a well-established safety profile in pregnancy) 
with labetalol (currently recommended as first-line by national UK guidance).. 
 
METHODS 
The study was an open-label, phase four, randomised controlled clinical trial (EudraCT 
Number 2013-003144-23), registered with International Standard Randomised Controlled 
Trials Number (DOI 10.1186/ISRCTN40973936, www.isrctn.com); the protocol, and other 
study literature were approved by the UK Research Ethics Committee (REC number 
13/EE/0390). Women of varied ethnicities were enrolled by study investigators using 
written informed consent at four consultant-led National Health Service (NHS) obstetric 
units in the United Kingdom (Guy’s and St Thomas’ NHS Foundation Trust, Central 
Manchester University NHS Foundation Trust, University of Leicester Hospitals NHS Trust 
and St George’s University Hospitals NHS Foundation Trust). The eligibility criteria included: 
  HYPE201709972-R1
   
 
5 
 
women with a prenatal diagnosis of chronic hypertension (treated or untreated) or blood 
pressure (BP) readings ≥140 mm Hg systolic or ≥/90 mm Hg diastolic prior to 20 weeks’ 
gestation requiring antihypertensive treatment prior to 27+6, as defined by the 
International Society for the Study of Hypertension in Pregnancy,14 gestation between 12+0 
and 27+6 weeks (to allow for second trimester blood pressure nadir), singleton pregnancies, 
aged over 18 years, and the ability to provide written informed consent. Women were 
excluded if they had a contraindication (relative or absolute) to either antihypertensive 
agent, such as labetalol in women with asthma. Details of the randomisation process, 
intervention and outcome measures are contained in the Supplemental Material 
(Supplemental Methods: Randomisation, Intervention and Outcome Measures). 
 
Statistical analysis 
For the primary analysis, the intention to treat principle was applied; women were analysed 
in the groups into which they were randomly allocated regardless of allocation received. The 
statistical software Stata/SE version 14 for Windows was used for all analyses. The number 
and percentage were calculated for binary and categorical variables. The mean and standard 
deviation (SD) or the median and interquartile range (IQR) were calculated for continuous 
variables. Linear regression with robust standard errors (SE) were used for the primary and 
other continuous outcomes. Adjustment was made for baseline covariates including, 
ethnicity (Black (determined by self-report of whether the woman had a parent or 
grandparent who was African or Caribbean) versus non-Black (all other ethnicities)), 
gestational age at randomisation, and centre. For continuous measures, an adjustment was 
also made for corresponding baseline measurement (systolic BP at randomisation for the 
primary clinical outcome).  For binary outcomes, binary regression with a log link was used 
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to calculate risk ratios (RR). Analysis of the primary clinical outcomes was repeated 
excluding women delivering their baby before 24 completed weeks of pregnancy, as women 
who deliver before viability did not complete the intended course of treatment.  
 
Subgroup analyses assessing the impact of ethnicity on treatment efficacy were performed 
using linear regression adjusting for baseline co-variates.  Results are reported for both 
groups and an interaction test carried out for any moderation of the treatment effect by the 
subgroup. A sensitivity analysis was also performed to evaluate the impact of date recruited 
on the primary outcome, using linear regression with a treatment × time interaction. 
Explanatory analysis of longitudinal urinary protein: creatinine ratio (PCR) (excluding women 
with chronic kidney disease) and pulse wave measures was conducted using interval 
regression models on log-transformed data allowing for gestation effects and the baseline 
measures. Group means and treatment effects were calculated as geometric means and 
ratios of geometric means given that log transformations were used. Serious adverse events 
and adverse events were collated and listed by allocation and grouped by symptom. 
Treatment effects were calculated as estimated differences in the mean or risk ratios with 
95% confidence intervals.  
 
RESULTS 
Between August 2014 and October 2015, 265 women were screened to enter the trial 
(Figure 1), of whom 65% met all eligibility criteria. Nine women (3%) were ineligible as they 
had a concurrent diagnosis of asthma and labetalol was therefore contraindicated. There 
were no women with a contraindication to nifedipine modified release. Of eligible women, 
66% agreed to participate. The most common reason given for declining participation was 
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reluctance to change from current antihypertensive therapy. Recruitment stopped when the 
enrolment target was reached as per the pre-specified primary process outcome. 114 
women with singleton pregnancies and a diagnosis of chronic hypertension were 
randomised to first-line antihypertensive therapy with either labetalol (n=56) or nifedipine 
(n=58). The participants not included in the analysis included one woman lost to follow-up 
(she emigrated during her pregnancy), and one who withdrew due to time constraints 
waiting for dispensing from the clinical trials pharmacy (no further information was 
available).  
 
Most baseline maternal characteristics at enrolment were similar between treatment 
groups (Table 1), except that time from diagnosis of chronic hypertension to study entry was 
longer in the labetalol group (54 versus 20 months), and the number of women with renal 
disease (labetalol n=5 versus nifedipine n=9) and diabetes (labetalol n=5 versus nifedipine 
n=8) at study entry was higher in the nifedipine group. The results were adjusted allowing 
for these differences, but this had no significant impact on the outcomes observed (P=0.29).  
 
Feasibility Outcomes 
The feasibility of conducting this trial in women with chronic hypertension in pregnancy was 
confirmed (Table 2), with the enrolment target reached over 14 months. Recruitment rate 
was 2.6 women per month (range of 1.2-3.7 per month). Disparity in recruitment rate by 
centre was associated with variation in the incidence of chronic hypertension in pregnancy 
at each centre. Women self-identifying as of Black ethnicity accounted for 56% of those 
enrolled, confirming feasibility of recruiting women of differing ethnic backgrounds. 
Geographical variation in the proportion of Black women enrolled was seen reflecting the 
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demographics of the local population of each hospital. The assigned intervention was 
discontinued by 12 women due to side effects of the medication; seven (13%) in the 
labetalol arm and five (9%) in the nifedipine arm. 
 
Clinical Outcomes 
Labetalol and nifedipine demonstrated effectiveness at controlling BP to therapeutic target 
in women with chronic hypertension in pregnancy (mean BP post-randomisation: labetalol 
134/84 mm Hg versus nifedipine 134/85 mm Hg). No difference was observed in highest 
brachial BP following randomisation to either treatment arm (Table 3). Sensitivity analyses 
included a per-protocol analysis excluding those who withdrew from their assigned 
intervention, analysis excluding those who delivered before 24 weeks’ gestation, and 
evaluating the impact of date recruited; there was no impact on the results for any of these 
analyses. Further analysis of the number of days with brachial BP readings out of target 
≥160 mm Hg systolic, ≥150 mm Hg systolic, and <80 mm Hg diastolic demonstrated no 
difference between treatment groups.  
 
Secondary maternal and perinatal outcomes (Table 4) showed more women receiving 
nifedipine developed superimposed pre-eclampsia than those allocated labetalol, but these 
differences were not significant (RR 1.78; 0.84-3.77). The same number of women in each 
group were diagnosed with early onset superimposed pre-eclampsia prior to 34 weeks’ 
gestation (n=6 (11%) in each treatment group). The number of women requiring additional 
oral antihypertensive agents was comparable between groups. There was a greater 
proportion of women treated with intravenous antihypertensive agents in the nifedipine 
group (14% versus 4%). The proportions of women requiring induction of labour and 
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caesarean section were comparable. The median gestation at delivery was similar between 
groups. Adverse maternal outcomes were reported for 6 (11%) women in the labetalol arm 
compared to 8 (14%) in the nifedipine arm (Supplemental Table S1).  
 
Six women delivered their baby before 24 weeks and three women had a stillbirth after 24 
weeks’ gestation. Four had late miscarriages (one in the labetalol group and three in the 
nifedipine group). Two women (one in each treatment group) underwent second trimester 
termination of pregnancy after enrolling in the study (one for abnormal amniocentesis 
result post-randomisation and one for severe early onset growth restriction). There were 
two stillbirths in the labetalol group (both with severe early onset growth restriction) and 
one in the nifedipine group (trisomy 13 diagnosed on amniocentesis after study enrolment). 
There was no significant difference in mean birthweight: 2960 g in the labetalol arm versus 
2730 g in the nifedipine arm (adjusted mean difference -240 g; -590, 110 g). There was a 
high proportion of babies born below the 10th and 3rd birthweight centile in each treatment 
group. Neonatal unit admission was slightly lower in the labetalol group compared to the 
nifedipine group (22% versus 29%). Adverse neonatal outcomes were reported for 11 (22%) 
infants in the labetalol arm and 17 (33%) infants in the nifedipine arm (Supplemental Table 
S2). Maternal and neonatal health resource use was similar between treatment groups 
(Supplemental Table S3).  
 
A pre-specified exploratory subgroup analysis of the impact of ethnicity on efficacy of each 
treatment did not show any significant difference in mean systolic or diastolic brachial BP in 
Black women (systolic 0.5 mm Hg; -4 to 5 mm Hg; diastolic 0.1 mm Hg; -3 to 3 mm Hg). No 
difference in mean systolic BP was seen between treatment groups in the non-Black women 
  HYPE201709972-R1
   
 
10 
 
(-0.4 mm Hg; -4 to 3 mm Hg), but a 4 mm Hg (-6.6 to -0.8 mm Hg; P=0.015) reduction in 
mean diastolic BP was seen in the labetalol arm in non-Black women. 
 
Mechanistic Outcomes 
Pulse wave analysis was performed in a subgroup of 83 women at three centres (nifedipine 
n=43, labetalol n=40). There was a mean 7.4 mm Hg decrease (-0.4 to -14.4 mm Hg) in 
central aortic pressure between randomisation and delivery in those assigned nifedipine 
compared to labetalol; this difference in reduction of central pressure was not observed in 
the peripheral blood pressures, which were the same between treatment groups. 
Augmentation index was 8.2% lower (-3.0 to -13.3%) in those assigned nifedipine compared 
to labetalol, though a sensitivity analysis examining the impact of centre on this finding 
demonstrated significant variation in this parameter by centre. There was no significant 
difference in pulse wave velocity between treatment groups (Table 3). 
 
Analysis of gestational change in urinary PCR by treatment group included samples from 73 
women (collected at three centres) without chronic kidney disease (nifedipine n=35, 
labetalol n=38). The PCR increased by 44% (21 to 71%) across gestation post-randomisation 
in women assigned nifedipine compared to women prescribed labetalol (Supplemental 
Figure S1). The mean PCR post-randomisation was 11.5 mg/mmol (SD 1.9) in the nifedipine 
group compared to 7.5 mg/mmol (SD 1.8) in the labetalol group.  The analysis was repeated 
excluding the women who developed superimposed pre-eclampsia (labetalol n=35 versus 
nifedipine n=27) with minimal effect on the results; PCR increased by 43% (18 to 74%) and 
the mean PCR post-randomisation was 11.5 mg/mmol (SD 1.9) in the nifedipine group 
compared to 7.4 mg/mmol (SD 1.9) in the labetalol group.  
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Adverse Events and Acceptability 
There were four Serious Adverse Events reported, all for unplanned hospital admissions not 
related to the pregnancy; one was in the labetalol arm (admission for epistaxis) and three in 
the nifedipine arm (one case of gastroenteritis, one case of deep vein thrombosis and one 
case of influenza). None were deemed to be related to the assigned intervention. The 
adverse events reported are presented in Supplemental Table S4 and are consistent with 
the Summary of Product Characteristics as expected side-effect profile for each drug. In the 
labetalol group, 21 (38%) women reported an adverse event compared to 15 (26%) in the 
nifedipine group. The postnatal questionnaire was answered by 34% of the women who 
completed the study. When asked if they would take the same treatment again in another 
pregnancy, 72% of the women taking labetalol said they ‘definitely would’ compared to 90% 
of those assigned nifedipine, and 11% of those assigned labetalol said they ‘probably would 
not’ take the treatment again compared to 5% of those assigned nifedipine.    
 
DISCUSSION 
To our knowledge this is the first randomised controlled trial comparing labetalol and 
nifedipine for control of chronic hypertension in pregnancy. The maximum and mean BP 
post-randomisation were comparable between treatment groups; given the 
contraindications and potential side effects of these drugs, evidence that they have similar 
ability to control hypertension to treatment target is beneficial. Evidence from the Control 
of Hypertension In Pregnancy Study  demonstrates maternal benefit of ‘tight control’ of BP 
utilising antihypertensive agents in reducing the incidence of severe hypertension without 
an increase in adverse perinatal outcomes.9 This is the largest head-to-head trial in pregnant 
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women with chronic hypertension assessing effectiveness of antihypertensive agents in 
controlling BP. Randomised controlled trials comparing antihypertensive treatment of 
chronic hypertension in pregnancy are limited and most were conducted at least 20 years 
ago; only three previous head-to-head studies (total 101 women) have compared the 
incidence of severe hypertension between randomised treatment groups (RR 1.1; 0.71-
1.81).1 This study was not powered to assess variation in the secondary maternal and 
perinatal outcomes, so further larger trials should evaluate differences in the incidence of 
superimposed pre-eclampsia, preterm delivery and small for gestational age infants. 
Variation in treatment effect by ethnicity was also noted, with labetalol having a greater 
effect on reducing diastolic BP in non-Black women, as previously demonstrated with beta-
blocker use outside pregnancy.15 The clinical significance of this potential difference needs 
to be established.  
 
Recruitment to randomised controlled trials of medication in pregnancy is challenging in 
view of the real and perceived risk of fetal harm. We confirmed the feasibility of conducting 
a randomised controlled trial investigating effectiveness of first-line antihypertensive agents 
for the treatment of chronic hypertension in pregnancy. Of the women meeting all eligibility 
criteria to enter the study, two-thirds consented to participation and 98% completed the 
study. Ethnic diversity in recruitment was also achieved, enabling investigation of variation 
in treatment efficacy. Demonstrating feasibility is important given the costly nature of large 
multicentre studies and need for suitable pragmatic designs to ensure definitive studies will 
fully answer the research questions posed.16  
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Nifedipine was associated with reduced central aortic pressure and augmentation index 
(markers of arterial stiffness). Calcium-channel blockers (versus beta-blockers) have been 
demonstrated to lower central aortic pressure in the Conduit Artery Functional Endpoint 
Study (non-pregnant hypertensive population).17 The exact mechanism behind these 
haemodynamic differences is not clear, but this finding in combination with the Anglo 
Scandinavian Cardiac Outcomes Trial results (of which the Conduit Artery Functional 
Endpoint Study was a subgroup analysis) suggested a greater decrease in long term 
cardiovascular risk with calcium-channel blockers as first-line antihypertensive agent 
compared to beta-blockers, perhaps mediated through reduction in central aortic 
pressure.18 National guidance no longer recommends beta-blockers as first-line 
antihypertensive treatment outside pregnancy; calcium-channel blockers are recommended 
as first-line antihypertensive treatment in Black women and angiotensin converting enzyme 
inhibitors (avoided in pregnancy due to fetal risks) are recommended for women under 55 
years of age of other ethnic backgrounds.11 African and Caribbean women are at increased 
risk of chronic hypertension and its associated cardiovascular morbidity, from a younger age 
than women of other ethnic origins.19 There is evidence that maternal and perinatal 
outcomes vary by ethnic background.13 The implications of first-line treatment 
recommendations outside pregnancy on the selection of antihypertensive agents in 
pregnancy needs to be established. 
 
Increased proteinuria across gestation with nifedipine  (compared to labetalol) was 
demonstrated even when those who developed superimposed pre-eclampsia and with pre-
existing renal disease were excluded from the analysis. Proteinuria is known to increase 
across gestation in normotensive pregnancy due to increased glomerular filtration.20 In this 
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cohort the mean PCR increased post study enrolment by 2.4 mg/mmol. It is not clear if the 
difference in proteinuria between treatment groups is a beneficial effect of labetalol or a 
side effect of nifedipine on renal function, and the clinical significance is unclear given the 
concentrations fall within the normal range. It seems probable that this is a side effect of 
nifedipine given similar findings in a Cochrane systematic review of an increase in 
proteinuria/pre-eclampsia in women with mild to moderate hypertension in pregnancy 
randomised to calcium-channel blockers versus none (four studies, 725 women; RR 1.40 
(1.06-1.86)),7 however the difference in the incidence of pre-eclampsia between treatment 
groups within our study was not significant. Studies in non-pregnant individuals with 
hypertension and chronic kidney disease suggest that dihydropyridine calcium-channel 
blockers (including nifedipine) are less effective at reducing proteinuria and therefore offer 
less renal protection than other antihypertensive agents.21 Investigation into the mechanism 
behind these differences has suggested that glomerular hypertension may be caused by 
dihydropyridine calcium-channel blockers that dilate the afferent but not the efferent renal 
arterioles.22 The variation in mechanism of action of antihypertensive agents in pregnancy 
needs to be explored further given that crossing a threshold of proteinuria is utilised in the 
diagnosis of pre-eclampsia; however the benefits of hypertensive control may outweigh a 
small increase in proteinuria.  
 
The strengths of this study include enrolment at four UK centres, reducing the risk of clinical 
practice bias. The study was designed and conducted as a randomised controlled trial in-line 
with CONSORT guidance.23 A computer-generated minimisation protocol was used to 
ensure balance within groups of maternal baseline characteristics. This reduced the risk of 
imbalance of baseline characteristics within treatment arms affecting the outcomes of the 
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study. The study enrolled women with primary and secondary hypertension (predominantly 
due to renal disease), which increases generalisability of the results; however this 
introduced potential bias as reflected in the imbalance of women with chronic kidney 
disease and diabetes between treatment groups. 
 
Whilst this study has confirmed feasibility, a larger definitive study is required to assess 
further the effectiveness of labetalol and nifedipine as antihypertensive treatment in 
pregnancy complicated by chronic hypertension. The study was not powered to answer the 
additional question of ethnic variation in effectiveness of first-line antihypertensive agents 
in pregnancy, but demonstrated the feasibility of recruiting women of many ethnic groups. 
The study was open-label subjecting the results to potential performance bias.24 It was 
considered clinically not feasible to mask allocation to clinicians and women in view of the 
differing recommended dosing frequency and need to escalate treatment and add a second 
agent where needed. Criteria for addition of second or third antihypertensive agent were 
not stipulated in the protocol, as this study aimed to investigate pragmatic clinical 
effectiveness rather than efficacy. Although methyldopa was considered for inclusion in the 
comparison, the sites chosen for this feasibility study indicated that methyldopa was not 
used as a first-line antihypertensive agent in their practice and thus a head-to-head labetalol 
versus nifedipine comparison was undertaken. Recent evidence (though not from a 
randomised head-to-head comparison) suggested that this agent may be associated with 
benefit in maternal and perinatal outcome compared to labetalol, and it should be 
considered for inclusion in a definitive trial.25 In the non-pregnant population there is 
evidence that some antihypertensive agents have additional therapeutic benefits beyond 
reduction in arterial blood pressure, including anti-inflammatory and oxidative stress 
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lowering properties.26 Given the role of inflammation and oxidative stress in the 
pathophysiology of pre-eclampsia,27 future research should further explore the mechanistic 
actions of each drug to establish  if other therapeutic benefits exist in pregnancy. In 
addition, given the variation in dosing regimens and side effect profiles of the first-line 
antihypertensive agents prescribed in pregnancy, future studies should further assess 
adherence and acceptability of individual agents.    
  
PERSPECTIVES 
Labetalol and nifedipine control mean systolic and diastolic BP to target in pregnant women 
with chronic hypertension. Good recruitment was demonstrated and mechanistic treatment 
effects observed. This study provides support for a larger definitive trial scrutinising the 
benefits and side effects of first-line antihypertensive treatment in pregnancy complicated 
by chronic hypertension. 
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NOVELTY AND SIGNIFICANCE:  
1) What is new?  
• Labetalol and nifedipine are both effective at lowering brachial blood 
pressure in pregnancy complicated by chronic hypertension.  
• Labetalol reduces brachial diastolic blood pressure more than nifedipine in 
non-Black women.  
• Nifedipine reduces central aortic blood pressure significantly more than 
labetalol in women of varying ethnicities. 
2) What is relevant? 
• Chronic hypertension in pregnancy is associated with adverse maternal and 
perinatal outcome 
• The optimal antihypertensive agent(s) is yet to be identified 
• Ethnic variation in antihypertensive treatment effect in women with chronic 
hypertension in pregnancy is evident and warrants further exploration 
• Labetalol and nifedipine demonstrate differing mechanistic treatment effects 
and the clinical importance of these requires investigation  
3) Summary 
This study provides support for a larger definitive trial scrutinising the 
benefits and side effects of first-line antihypertensive treatment in pregnant 
women with chronic hypertension.  
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FIGURE LEDGENDS: 
Figure 1: Flow diagram of trial participants  
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TABLES: 
Table 1: Baseline maternal characteristics at enrolment 
Characteristic 
Randomised to 
labetalol 
n=56 
Randomised to 
nifedipine 
n=58 
Age at enrolment*, years 36.0 (32.0-39.1) 35.0 (30.3-38.5) 
Gestational age at randomization*, weeks 16.6 (13.7-21.3) 16.9 (14.6-21.1) 
Ethnicity†    
Black  30 (54%) 32 (55%) 
White 17 (30%) 18 (31%) 
Asian 6 (11%) 3 (5%) 
Other 3 (5%) 5 (9%) 
Current smoker† 1 (2%) 1 (2%) 
Body mass index‡, kg/m2 31.2 (7.1) 30.5 (4.9) 
Nulliparous women† 14 (25%) 13 (22%) 
Time since diagnosis of chronic 
hypertension*, months  
53.5 (8.3-109.5) 20.4 (1.1-75.1) 
Type of Chronic Hypertension†   
Primary 51 (91%) 48 (83%) 
Secondary§  5 (9%) 10 (17%) 
Diabetes mellitus (type I or type II)† 5 (9%) 8 (14%) 
Renal disease† 5 (9%) 9 (16%) 
BP at study entry*, mm Hg   
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Systolic 143 (133-150) 141 (132-151) 
Diastolic 92 (85-98) 91 (86-96) 
Antihypertensive medication taken at 
study entry† 
41 (73%) 38 (66%) 
* median and interquartile range, † number and percentage, ‡ mean and standard 
deviation, § predominantly due to renal disease  
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Table 2: Summary of feasibility outcomes 
Feasibility outcome 
Total number enrolled 
n=114 
Women enrolled per centre  
number (%) 
 
Guy’s and St Thomas’ NHS Foundation Trust 56 (49%) 
Central Manchester University Hospitals NHS Foundation Trust 33 (29%) 
University Hospitals of Leicester NHS Trust  12 (11%) 
St George’s University Hospitals NHS Foundation Trust 13 (11%) 
Enrolment rate per centre  
(women enrolled per month site recruiting) 
 
Guy’s and St Thomas’ NHS Foundation Trust 3.7 
Central Manchester University Hospitals NHS Foundation Trust 2.8 
University Hospitals of Leicester NHS Trust 1.2 
St George’s University Hospitals NHS Foundation Trust 1.9 
Mean of all centres 2.6 
Proportion of those enrolled of Black ethnicity  
Guy’s and St Thomas’ NHS Foundation Trust 70% 
Central Manchester University Hospitals NHS Foundation Trust 46% 
University Hospitals of Leicester NHS Trust 17% 
St George’s University Hospitals NHS Foundation Trust 77% 
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Table 3: Effect of treatment on brachial blood pressure and pulse wave analyses 
 
Randomised 
to labetalol 
n=55 
Randomised to 
nifedipine 
n=57 
Adjusted mean 
difference 
(95% Confidence 
Interval) 
Maximum brachial BP, mm Hg    
Systolic 161 (14.7) 163 (19.2) 1.2 (-4.9 to 7.2) 
Diastolic 101 (10.2) 105 (11.7) 3.3 (-0.6 to 7.3) 
Mean brachial BP, mm Hg    
Systolic 134 (8.5) 134 (9.2) 0.3 (-2.8 to 3.4) 
Diastolic 84 (6.6) 85 (5.5) -1.9 (-4.1 to 0.3) 
 n=42 n=45  
Central aortic pressure, mm Hg 132 (20.2) 126 (12.9) -7 (-0.4 to -14.4) 
Augmentation index, % 21 (14.9) 13 (11.7) -8.2 (-3.0 to -13.3) 
Pulse wave velocity, m/s 8.8 (1.7) 8.7 (1.5) -0.1 (-0.4 to 0.7) 
Results adjusted for systolic BP at randomisation ethnicity, gestational age at randomisation 
and centre. Pulse wave analyses were only assessed at three sites, which accounts for the 
reduction in the number of participants presented. 
 
  
  HYPE201709972-R1
   
 
28 
 
Table 4: Secondary maternal and perinatal outcomes 
 
Randomised to 
labetalol 
n=55 
Randomised to 
nifedipine 
n=57 
Adjusted 
difference in 
mean/median or 
RR (95% CI) 
Time between randomisation 
and delivery*, days 
134 (39) 127 (44) 
 
Superimposed pre-eclampsia† 8 (15%) 15 (26%) 1.78 (0.84-3.77) 
Superimposed pre-eclampsia 
<34 weeks† 
6 (11%) 6 (11%)  
Additional oral antihypertensive 
agents†ǁ 
   
0 37 (67%) 36 (63%)  
1 15 (27%) 20 (35%)  
≥2 2 (4%) 1 (2%)  
Additional intravenous 
antihypertensive agents† 
2 (4%) 8 (14%)  
Adverse maternal outcome†§ 6 (11%) 8 (14%)  
Mode of delivery†    
Spontaneous vaginal delivery 22 (40%) 21 (37%)  
Assisted vaginal delivery 2 (4%) 4 (7%)  
Elective prelabour LSCS 9 (16%) 13 (23%)  
Emergency prelabour LSCS 14 (26%) 11 (19%)  
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Emergency LSCS in labour 8 (15%) 8 (14%)  
Estimated blood loss at 
delivery*, ml 
600 (500) 610 (550) 
 
Gestation at delivery‡, weeks  38.6 (37.7-39.4) 38.0 (36.4-39.1) -0.6 (-1.3 to 0.1) 
Preterm birth <37 weeks†  12 (22%) 20 (35%)  
Preterm birth <34 weeks† 10 (18%) 11 (19%)  
Condition of fetus at delivery†    
Livebirth 51 (93%) 52 (91%)  
Miscarriage 1 (2%) 3 (5%)  
Termination of pregnancy 1 (2%) 1 (2%)  
Stillbirth 2 (4%) 1 (2%)  
Neonatal outcomes n=51 n=52  
Birthweight*, g  2957 (790) 2732 (883) -240 (-589 to 109) 
Birthweight <10th centile† 16 (31%) 17 (33%)  
Birthweight <3rd centile† 6 (12%) 10 (19%)  
Admitted to neonatal unit† 11 (22%) 15 (29%) 1.3 (0.7-2.5) 
Adverse perinatal outcome†§ 11 (22%) 17 (33%)  
*mean and standard deviation, † number and percentage, ‡ median and interquartile range, 
§details of adverse maternal and perinatal outcomes provided in Supplemental Table S1 and 
Supplemental Table S2, ǁ of those receiving additional oral antihypertensive agents, 94% 
(n=16) of the labetalol group were prescribed a calcium-channel blocker and 86% (n=18) of 
the nifedipine group were prescribed an alpha/beta-blocker. Results adjusted for ethnicity, 
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gestational age at randomisation and centre. Risk ratios only calculated for pre-specified 
secondary outcomes.  
